Quantcast

Latest Teva Pharmaceutical Industries Stories

2014-09-08 12:29:59

Commission Alleges That AbbVie Inc. and Besins Healthcare Inc. Filed Sham Lawsuits; AbbVie and Teva Pharmaceuticals USA, Inc. Entered Anticompetitive Agreement to Delay Generic Entry WASHINGTON, Sept. 8, 2014 /PRNewswire-USNewswire/ -- In its latest action to ensure competition in the nation's healthcare markets, the Federal Trade Commission has filed a complaint in federal district court charging several major pharmaceutical companies with illegally blocking American consumers' access to...

2014-08-28 12:29:56

PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration (FDA). This product is the generic version of Teva's Copaxone® 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS)....

2014-06-18 12:36:07

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Parkinson's Disease: World Drug Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/parkinson_s_disease_world_drug_industry_market_2014_2024.html Report DetailsTreating Parkinson's - how you find business trends, R&D, and revenue forecastsSee the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research...

2014-04-28 16:31:49

DUBLIN, April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex(®) (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Actavis maintains that the FDA improperly awarded sole exclusivity on generic Celebrex(®) to...

2014-04-24 16:29:32

- John R. Miller Retires - EAST RUTHERFORD, N.J., April 24, 2014 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") announced today that the Board of Directors has elected Shlomo Yanai as its new Non-Executive Chairman of the Board effective immediately following the retirement of John R. Miller. Mr. Miller has served as Non-Executive Chairman since 2008 and has been a member of the Cambrex Board of Directors since 1998. His retirement is effective April 24, 2014. "I would...

2014-04-24 08:34:30

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-04-03 12:30:06

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical...

2014-04-01 08:27:28

LONDON, April 1, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Inhalation & Nasal Spray Generic Drugs 2013 Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted combined revenues of around US$18.0 billion in 2012. All five are...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related